BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program - Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR...

Vyriad Inc. to Present Clinical Trial Updates for its Oncolytic Virotherapies at Virtual 2020 ASCO Annual Meeting ROCHESTER, Minn., May 29, 2020 (GLOBE NEWSWIRE) -- Vyriad, Inc. announced today that it will present data and information about the design of clinical trials evaluating its oncolytic viruses at the...

Florida Cancer Specialists Participation at ASCO® Demonstrates Progress Made Through Clinical Research Fort Myers, Fla., May 27, 2020 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) physicians are the co-authors of 20 research studies that will be presented at the...

Innate Pharma to Present New Efficacy Data for Monalizumab in Combination With Cetuximab in Head and Neck Cancer at the ASCO20 Virtual Scientific Program Phase II expansion cohort of “IO-pretreated patients” demonstrates 20% overall response rate Data confirm previous preliminary efficacy data seen in this subpopulation MARSEILLE, France,...